期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

基于ISAfE指标的我国调血脂类基本药物再评价初探 被引量：2

Discussion of the Evaluation Index for China's Essential Medicine——A case study of Antilipemic Agents
原文传递
导出
摘要 目的:通过ISAfE指标评价我国调血脂类基本药物的遴选。方法:综合运用文献研究及比较分析和统计分析的方法进行实证研究。结果与结论:我国调脂类基本药物的遴选符合基本药物的一般要求,ISAfE指标的初探为今后基本药物再评价提供了参考。 Objective： To evaluate the selection of essential drugs for Antilipemic by ISAFE index. Method： The empirical research has been conducted, combining the use of literature research, comparative analysis and statistical analysis. Results and Conclusion： The selection of essential drugs for Antilipemic in China is in line with the requirements of essential drugs, and the primary research of ISAfE index could provide a reference for reevaluation of essential drugs in the future.
作者 李奕璋 邵蓉
机构地区 中国药科大学国际医药商学院医药产业发展研究中心
出处 《中国药物经济学》 2011年第1期56-63,共8页 China Journal of Pharmaceutical Economics
关键词 ISAfE 调血脂 药基本药物 评价 ISAfE Antilipemic Agents Essential drugs Evaluation
分类号 R954 [医药卫生—药学]
  • 相关文献

参考文献15

  • 1匡丽萍,兰海霞.我院2004-2007年降血脂药物应用分析[J].西北药学杂志,2009,24(2):152-152. 被引量：8
  • 2P CHONGTRAKUL,N SUMPRADIT.ISafE and the evidencebased approach for essential medicines selection in Thailand[J].ESSENTIAL DRUGS MONITOR,2005,34:18-19.
  • 3鄢琳,曹立亚,雷建军,兰奋,李静,肖爱丽,邹燕,白雪,章渝,王超,张力文,李幼平.9种调血脂药物有效性及安全性评价[J].中国循证医学杂志,2005,5(1):8-21. 被引量：50
  • 4Downs JR,C learfieldM,Weis S,Whitney E,Shapiro DR,BeerePA,LangendofferA,Stein EA,KruyerW,Gotto AM Jr.Prmiary Prevention of Acute Coronary Events with Lovastatin inMen and Women With Average Cholesterol Levels.Results of AFCAPS/Tex-CAPS[J] JAMA,1998,279(5):1615-1622.
  • 5Kong SX,Crawford SY,Gandhi SK,Seeger JD,Schumock GT,Lam NP,Stubbings J,SchoenMD.Efficacy of 3-hydroxy-3-methyl-glutary coenzyme a reductase inhibitors in the treatment of patientswith hypercholesterolemia:a meta-analysis of clinical trials[J].ClinTher,1997,19(4):778-797.
  • 6John Kjekshus,Terje R,Pedersen.R educing the Risk of Coronary Events:Evidence from the Scandinavian Smi vastain Survival Study(4S)[J].Am JCardiol,1995,76(9):64C-68C.
  • 7Heart Protection Study Collaborative Group.MRC/BHF Heart pro-tection Study of antioxidant vitam in supplementation in 20536 high-risk individuals:a random ized placebo-controlled trial[J].Lancet,2002,360(7):7-22.
  • 8FrickMH,EIo O,HaapaK,Heinonen OP,Heinsaral iP,Helo P,I-luttunen JK,Kaitaniem iP,Koskinen P,M aaninen V,et a.l HelsinkiHeartStndy:prmi ary-prevention trialwith gemfibrozil into iddle-agedmen with dyslipidem ia.Safety of treatmen,t changes in risk fac-tors,and incidence of coronary heart disease[J].N Engl JMed,1987,317 (20):1237-1245.
  • 9SteinerG,StewartD,Hosking JD.Effect of fenofibrate on progres-sion of coronary-artery disease in type 2 diabetes:the Diabetes Athero-sclerosis Intervention Study,a random ised study[J].Lancet.2001,357(9260):905-910.
  • 10Serruys PW,De Feyter PJ,Benghozi R,Hugenholtz PG,LesaffreE.The Lescol (R) Intervention Prevention Study (LIPS):a double-blind,placebo-controlled,randomized trial of the longterm effects of fluvastatin after successful transcatheter therapy in patientswith coronary heartdisease[J].Int J Cardiovasc Intervent,2001,4(4):165-172.

二级参考文献105

共引文献59

同被引文献32

  • 1国家卫生和计划生育委员会.药政司启动2012年度委托研究课题招标工作[EB/OL].(2012-02-16)[2013-05-08].http:Hwwwmoh.gov.on/mohywzc/s7652/201202/54134.shtml.
  • 2WHO. Standard treatment guidelines and essential drugs list for South Africa, hospital level, adults. Second edition, 2006 [EB/OL]. [2013-05-08]. http://apps.who.int/medicinedocs/en/m/ abstract/Js18259en.
  • 3郭莹,邢花,袁红梅,等.国外基本药物目录遴选经验对我国的启示[c].2012年中国药学会药事管理专业委员会年会暨“卜二五”医药科学发展学术研讨会论文集.北京:中国药学会,中国药事编辑部,2012:321-324.
  • 4Chongtrakul P, Sumpradit N, Yoongthong W. ISafE and the evi- dence-based approach for essential medicines selection in Thai- land[EB/OL]. [2013-05-06]. http://www.nlem.in.th/sites/default/ files/drugsmonitor34-p 18-190.pdf.
  • 5王京丽,贾秀虹.“沙坦”类药物的研究进展[J].国际药学研究杂志,2007,34(6):434-438. 被引量：17
  • 6卫生部,国家发展和改革委员会,和信息化部,等.关于建立国家基本药物制度的实施意见[EB/OL]. (2009-08-18) [2015-08-09 ]. http: //www. nhfpc. gov. cn/zhuzhan/wsbmgz/201304/f2a0d9cbc33f45e091a9d4a936c6?e58. shtml.
  • 7World Health Organization. WHO medicines strategy: Revised proce-dure for updating WHOf s Model List of Essential Drugs [ EB/OL ].(2001-12-07) [2014-08-02]. http://apps. who. int/ gb/archive/pdf_files/EB109/ eebl098. pdf.
  • 8Chongtrakul P, Sumpradit N, Yoongthong W. ISafE and the evidence-based approach for essential medicines selection in Thailand [ J ].Essential drugs monitor, 2005 , 34: 18-19.
  • 9Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angio-tensin II antagonists valsartan and losartan in the treatment of essentialhypertension[j]. Am J Hypertens, 1999, 12(4 R 1) : 414-417.
  • 10Wang L, Zhao JW, Liu B, et al. Antihypertensive effects of olmesar-tan compared with other angiotensin receptor blockers : a meta-analysis[J]. Am J Cardiovasc Drugs, 2012, 12(5) : 335-344.

引证文献2

二级引证文献5

中国药物经济学
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部